<DOC>
	<DOCNO>NCT00107029</DOCNO>
	<brief_summary>This protocol study HIV+ young people identify certain HIV-1 specific T-cell response genetic marker previously enrol 5-year longitudinal adolescent study , `` REACH . '' Blood sample collect , medical medication history physical examination perform every 6 month total 2 year .</brief_summary>
	<brief_title>Evaluation Genetic Markers Explanations Observed Differences Disease Progression HIV+ Youth</brief_title>
	<detailed_description>Numerous study demonstrate association HLA class I genotypes differ progression AIDS individual follow antiretroviral therapy . These study always associate HLA class I alleles risk HIV-1 disease progression ; however consistently demonstrate HLA-B*35 B*53 portend bad outcome compare well outcome observed HLA-B*27 B*57 carrier . Despite information , little data exists explain mechanism association . This longitudinal study look HIV-1 specific CD8+ T-cell response dominant HIV-1 genotype among individual identify HLA-B*27 , B*35 , B*53 B*57 positive study do collaboration REACH project .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>HLAClass I HLAB*27 , B*35 , B*53 and/or B*57 positive identify REACH study Subject 's ability willingness provide write informed consent Subject 's ability willingness follow least one year ATN 026 study On chronic immunosuppressive therapy , include topical inhaled steroid use . Any prohibited medication list protocol within 2 week prior Entry visit lab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>CD8+ T-cells</keyword>
	<keyword>HIV-1 genotype</keyword>
</DOC>